1. Scrip
  2. >>Business

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

 
• By Anju Ghangurde

More legal action in India that has the Bolar exception provision at its crux with Roche, in this instance, warding off a local drug maker in the Evrysdi patent infringement case.

Roche Thwarts Alleged Patent Infringing Activity • Source: Shutterstock

Roche appears to have thwarted, at least for now, an alleged infringement attempt pertaining to the patents for its oral spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) in India.

The case is among the many legal battles in India where innovator firms haul generic drug makers to court over suspicion of patent infringement, with the latter citing the Bolar provision – the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.